Clinical response to therapy with thymopoietin pentapeptide (TP-5) in rheumatoid arthritis

Abstract

The effect of thymopoietin pentapeptide (TP-5) was evaluated in patients with rheumatoid arthritis (RA). Ninety-two patients were divided into 3 groups, namely, placebo, TP-5 intramuscularly (IM) 1 mg, TP-5 intravenously (IV) 50 mg, and were evaluated for 6 measures of disease activity at the beginning of the study and at 3 and 6 months. No difference was observed between the placebo group and the group treated with TP-5 IM 1 mg. However, in the group treated with TP-5 IV 50 mg a statistically significant improvement of all parameters except the ESR was observed.

Die Anwendung von Thymus-Pr�paraten bei rheumatischen Erkrankungen

“…Diese sollen im Folgenden dargestellt werden [19,21,22,23,24,25]. Teilweise wurden die Untersuchungen placebokontrolliert und randomisiert durchgeführt.…”

FcIgG Receptor-Bearing Lymphocytes and Monoclonal Antibody-Defined T Cell Subsets in Atopic Dermatitis: Effect of Treatment with Thymopoietin Pentapeptide (TP-5)

“…Particularly, since this sub stance has been claimed to have an effect on rheuma toid arthritis in man [37] and to induce suppressor cell function in mice with autohemolytic anemia [22] it might a priori be considered to be of potential thera peutic use in patients with AD. In the study reported herein we show that patients with AD have deficient relative and absolute numbers of T cells with FcIgG and T8 markers and that TP-5 treatment appears to normalize these deficiencies.…”